Tarbox Family Office’s Corcept Therapeutics CORT Stock Holding History

Tarbox Family Office’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-88	Closed	-$2K	–	310
2022 Q1	$2K	Hold	88	–	–	﹤0.01%	785
2021 Q4	$2K	Hold	88	–	–	﹤0.01%	858
2021 Q3	$2K	Hold	88	–	–	﹤0.01%	904
2021 Q2	$2K	Sell	88 -25	-22%	-$556	﹤0.01%	911
2021 Q1	$3K	Hold	113	–	–	﹤0.01%	734
2020 Q4	$3K	Hold	113	–	–	﹤0.01%	666
2020 Q3	$2K	Buy	113 +25	+28%	+$398	﹤0.01%	744
2020 Q2	$1K	Buy	+88	New	+$1.24K	﹤0.01%	934

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tarbox Family Office's CORT Position: Q2 2022 in Review

Tarbox Family Office sold out of Corcept Therapeutics (CORT) in Q2 2022, closing a stake of 88 shares — an estimated $2K sold.

Tarbox Family Office first reported a position in CORT in Q2 2020 and held it in 8 quarters. The position peaked at $3K in Q1 2021. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

Tarbox Family Office reported no remaining Corcept Therapeutics position as of Q2 2022 after selling out during the quarter.
Tarbox Family Office sold 88 Corcept Therapeutics shares in Q2 2022, an estimated $2K.
Tarbox Family Office first reported a position in Corcept Therapeutics in Q2 2020 and held it in 8 quarters.
Tarbox Family Office's Corcept Therapeutics position peaked at $3K in Q1 2021.
225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on Tarbox Family Office's 13F filing for Q2 2022, filed 19 Jul 2022.